OncoMatch/Clinical Trials/NCT07040956
A Clinical Trial Comparing Low-Dose RT + Targeted Therapy+ Immunotherapy vs Targeted Therapy+ Immunotherapy Alone as Neoadjuvant Therapy in Operable HNSCC Patients.
Is NCT07040956 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Tislelizumab and Afatinib for head and neck squamous cell carcinoma.
Treatment: Tislelizumab · Afatinib — This study aimed to compare the efficacy of neoadjuvant low-dose radiotherapy combined with targeted therapy and immunotherapy versus targeted therapy and immunotherapy alone in patients with resectable head and neck squamous cell carcinoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: anti-PD-1 therapy
prior therapy with: anti-PD-1
Cannot have received: anti-PD-L1 therapy
prior therapy with: anti-PD-L1/2
Cannot have received: anti-PD-L2 therapy
prior therapy with: anti-PD-L1/2
Cannot have received: anti-CTLA-4 therapy
prior therapy with: anti-CTLA-4 antibody
Cannot have received: anti-EGFR antibody
prior therapy with: anti-EGFR antibody
Cannot have received: EGFR tyrosine kinase inhibitor
prior therapy with: EGFR-TKIs
Cannot have received: antitumor vaccine
prior therapy with: antitumor vaccine
Cannot have received: active vaccine
any active vaccine against an infectious disease within 4 weeks before the first dose or planned during the study period
Cannot have received: major surgery
major surgery or serious trauma within 4 weeks before the first dose
Cannot have received: investigational drug
Received any investigational drug within 4 weeks prior to the first dose
Lab requirements
Blood counts
Absolute neutrophil count ≥ 1.5 × 10^9/L, hemoglobin ≥ 80 g/L, platelets ≥ 80 × 10^9/L
Kidney function
Creatinine clearance ≥ 60 ml/min
Liver function
ALT, AST and ALP < 2.5× ULN, total bilirubin ≤ 2×ULN; albumin≥ 2.8 g/dL
Cardiac function
INR≤ 1.5, APTT≤ 1.5×ULN; ejection fraction < 50% excluded
Adequate organ and bone marrow function: Absolute neutrophil count ≥ 1.5 × 10^9/L, hemoglobin ≥ 80 g/L, platelets ≥ 80 × 10^9/L; ALT, AST and ALP < 2.5× ULN, total bilirubin ≤ 2×ULN; albumin≥ 2.8 g/dL；Creatinine clearance ≥ 60 ml/min；INR≤ 1.5, APTT≤ 1.5×ULN.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify